EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study

Mario Fontán-Vela iD, Victoria Hernando, Carmen Olmedo, Ermengol Coma iD, Montse Martínez, David Moreno-Perez, Nicola Lorusso, María Vázquez Torres, José Francisco Barbas Del Buey, Javier Roig-Sena, Eliseo Pastor, Antònia Galmés Truyols und 25 weitere

Clinical Infectious Diseases · 17.02.2024 · 78 (2) · 476-483

DOI: 10.1093/cid/ciad645 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.10.2023. Verfasst von Mario Fontán-Vela und 36 weiteren Autor:innen. Beteiligte Einrichtung: National Centre of Epidemiology, Institute of Health Carlos III, Community of Madrid, Spain. Hauptthemen laut MEDLINE: Vaccinia, Mpox, Monkeypox, Vaccines, HIV Infections. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With more than 7500 cases reported since April 2022, Spain has experienced the highest incidence of mpox in Europe. From 12 July onward, the modified vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for those receiving pre-exposure prophylaxis for human immunodeficiency virus (HIV-PrEP). Our aim was to assess the effectiveness of 1 dose of MVA-BN vaccine as pre-exposure prophylaxis against mpox virus (MPXV) infection in persons on HIV-PrEP.

Methods

National retrospective cohort study between 12 July and 12 December 2022. Individuals aged ≥18 years receiving HIV-PrEP as of 12 July with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of vaccine and unvaccinated controls of the same age and region. We used a Kaplan–Meier estimator, calculated risk ratios (RR) and vaccine effectiveness (VE = [1 − RR]x100).

Results

We included 5660 matched pairs, with a median follow-up of 62 days (interquartile range, 24–97). Mpox cumulative incidence was 5.6 per 1000 (25 cases) in unvaccinated and 3.5 per 1000 (18 cases) in vaccinated. No effect was found during days 0–6 post-vaccination (VE, −38.3; 95% confidence interval [CI], −332.7 to 46.4), but VE was 65% at ≥7 days (95% CI, 22.9 to 88.0) and 79% at ≥14 days (95% CI, 33.3 to 100.0) post-vaccination.

Conclusions

One dose of MVA-BN vaccine offered protection against mpox in most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VacciniaMpox, MonkeypoxVaccinesHIV InfectionsHumansAdolescentAdultCohort StudiesRetrospective StudiesVaccinia virusVaccinationMonkeypox virus

Stichwörter der Autor:innen

MVA-BN vaccinemonkeypoxmpoxpre-exposure prophylaxisvaccine effectiveness

Substanzen

Vaccines

Autor:innen und Institutionen

  • National Centre of Epidemiology, Institute of Health Carlos III, Community of Madrid, Spain.
  • Public Health and Epidemiology Research Group, School of Medicine and Health Sciences, Universidad de Alcalá, Alcalá de Henares, Community of Madrid, Spain.
  • CIBER on Infectious Diseases, Madrid, Spain.
  • Vaccination Programme, General Directorate of Public Health, Ministry of Health, Madrid, Spain.
  • Primary Healthcare Information Systems, Health Institute of Catalonia, Catalonia, Spain.
  • Preventive Medicine Service, General Sub-directorate for Health Promotion, Health Department, Secretariat of Public Health,Catalonia, Spain.

ORCID-Profile: Mario Fontán-Vela, Ermengol Coma, Susana Monge

Zitieren

APA

Fontán-Vela, M., Hernando, V., Olmedo, C., Coma, E., Martínez, M., Moreno-Perez, D., Lorusso, N., Vázquez Torres, M., Barbas Del Buey, J. F., Roig-Sena, J., Pastor, E., Galmés Truyols, A., Artigues Serra, F., Sancho Martínez, R. M., Latasa Zamalloa, P., Pérez Martínez, O., Vázquez Estepa, A., García Rojas, A. J., Barreno Estévez, A. I., …, & Spanish MPOX Vaccine Effectiveness Study Group (2024). Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study. Clinical Infectious Diseases, 78(2), 476-483. https://doi.org/10.1093/cid/ciad645

Vancouver

Fontán-Vela M, Hernando V, Olmedo C, Coma E, Martínez M, Moreno-Perez D, et al. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study. Clinical Infectious Diseases. 2024;78(2):476-483. doi:10.1093/cid/ciad645

BibTeX
@article{FontnVela2024,
  author = {Fontán-Vela, Mario and Hernando, Victoria and Olmedo, Carmen and Coma, Ermengol and Martínez, Montse and Moreno-Perez, David and Lorusso, Nicola and Vázquez Torres, María and Barbas Del Buey, José Francisco and Roig-Sena, Javier and Pastor, Eliseo and Galmés Truyols, Antònia and Artigues Serra, Francisca and Sancho Martínez, Rosa María and Latasa Zamalloa, Pello and Pérez Martínez, Olaia and Vázquez Estepa, Ana and García Rojas, Amós José and Barreno Estévez, Ana Isabel and Sánchez-Migallón Naranjo, Alonso and Pérez Martín, Jaime Jesús and Peces Jiménez, Pilar and Morales Romero, Raquel and Castilla, Jesús and García Cenoz, Manuel and Huerta Huerta, Marta and Boone, An Lieve Dirk and Macías Ortiz, María José and Álvarez Río, Virginia and Rodríguez Recio, María Jesús and Merino Díaz, María and Berradre Sáenz, Belén and Villegas-Moreno, María Teresa and Limia, Aurora and Diaz, Asuncion and Monge, Susana and Spanish MPOX Vaccine Effectiveness Study Group, Spanish MPOX Vaccine Effectiveness Study Group},
  title = {Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {2},
  pages = {476--483},
  doi = {10.1093/cid/ciad645}
}
Kostenlos starten →